Trevena (NASDAQ:TRVN) Coverage Initiated at StockNews.com

Stock analysts at StockNews.com initiated coverage on shares of Trevena (NASDAQ:TRVN) in a research report issued to clients and investors on Sunday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Trevena Trading Down 3.4 %

Shares of Trevena stock opened at $1.69 on Friday. The company has a market capitalization of $1.45 million, a PE ratio of -0.03 and a beta of 1.08. Trevena has a 12 month low of $1.13 and a 12 month high of $19.23. The stock’s fifty day simple moving average is $3.47 and its 200 day simple moving average is $6.08.

Trevena (NASDAQ:TRVN) last announced its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($9.25) by $9.02. The company had revenue of $0.33 million during the quarter. Analysts predict that Trevena will post -32.25 EPS for the current fiscal year.

Trevena Company Profile

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.